Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

References

• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015; 7(1):9-14; PMID:25529996; https://doi.org/10.4161/19420862.2015.989042
   PubMed Web of Science ®Google Scholar
• Boehm MK, Woof JM, Kerr MA, Perkins SJ. The fab and fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 1999; 286(5):1421-47; PMID:10064707; https://doi.org/10.1006/jmbi.1998.2556
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Hutchinson AT, Carter PJ. Therapeutic antibodies: Discovery, design and deployment. Mol Immunol 2015; 67(2):1-3; PMID:25990602; https://doi.org/10.1016/j.molimm.2015.05.004
   PubMed Web of Science ®Google Scholar
• Ueda T. Next-generation optimized biotherapeutics - A review and preclinical study. Biochim Biophys Acta 2014; 1844(11):2053-7; PMID:24954894; https://doi.org/10.1016/j.bbapap.2014.06.008
   PubMed Web of Science ®Google Scholar
• Suresh S, Fisher C, Ayyub H, Premawardhena A, Allen A, Perera A, Bandara D, Olivieri N, Weatherall D. Alpha thalassaemia and extended alpha globin genes in Sri Lanka. Blood Cells Mol Dis 2013; 50(2):93-8; PMID:23138098; https://doi.org/10.1016/j.bcmd.2012.10.001
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 2012; 3(4):73-97; PMID:22558487; https://doi.org/10.4331/wjbc.v3.i4.73
   PubMedGoogle Scholar
• Bumbaca D, Wong A, Drake E, Reyes AE, Lin BC, Stephan JP, Desnoyers L, Shen BQ, Dennis MS. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011; 3(4):376-86; PMID:21540647; https://doi.org/10.4161/mabs.3.4.15786
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368(3):652-65; PMID:17362988; https://doi.org/10.1016/j.jmb.2007.02.024
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Szklut P, Wensel D, Ross J, Xu X, Awwad M, Gill D, Tchistiakov L, Warner G. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, Anti-Abeta Ab2, in nonclinical species. Pharm Res 2011; 28(7):1696-706; PMID:21424161; https://doi.org/10.1007/s11095-011-0405-x
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8(2):e57479; PMID:23468998; https://doi.org/10.1371/journal.pone.0057479
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4(6):753-60; PMID:23778268; https://doi.org/10.4161/mabs.22189
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, et al. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010; 2(3):335-46; PMID:20424514; https://doi.org/10.4161/mabs.2.3.11850
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23(5):385-92; PMID:20159773; https://doi.org/10.1093/protein/gzq009
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A 2014; 111(52):18601-6; PMID:25512516; https://doi.org/10.1073/pnas.1421779112
   PubMed Web of Science ®Google Scholar
• Yadav DB, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. J Biol Chem 2015; 290(50):29732-41; PMID:26491012; https://doi.org/10.1074/jbc.M115.692434
   PubMed Web of Science ®Google Scholar
• Hötzel I, Chiang V, Diao J, Pantua H, Maun HR, Kapadia SB. Efficient production of antibodies against a mammalian integral membrane protein by phage display. Protein Eng Des Sel 2011; 24(9):679-89; PMID:21810920; https://doi.org/10.1093/protein/gzr039
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. MAbs 2012; 4(4):475-87; PMID:22699308; https://doi.org/10.4161/mabs.20737
   PubMed Web of Science ®Google Scholar
• Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013; 52(2):83-124; PMID:23299465; https://doi.org/10.1007/s40262-012-0027-4
   PubMed Web of Science ®Google Scholar
• Shi S. Biologics: An update and challenge of their pharmacokinetics. Curr Drug Metab 2014; 15(3):271-90; PMID:24745789; https://doi.org/10.2174/138920021503140412212905
   PubMed Web of Science ®Google Scholar
• Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS. Neonatal Fc receptor: From immunity to therapeutics. J Clin Immunol 2010; 30(6):777-89; PMID:20886282; https://doi.org/10.1007/s10875-010-9468-4
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 2015; 104(6):1885-98; PMID:25821140; https://doi.org/10.1002/jps.24430
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 2013; 5(5):787-94; PMID:23883920; https://doi.org/10.4161/mabs.25269
   PubMed Web of Science ®Google Scholar
• Sievers SA, Scharf L, West AP, Bjorkman PJ. Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS 2015; 10(3):151-9; PMID:25760931; https://doi.org/10.1097/COH.0000000000000148
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 2013; 5(4):576-86; PMID:23765230; https://doi.org/10.4161/mabs.24981
   PubMed Web of Science ®Google Scholar
• Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs 2016; 8(7):1269-75; PMID:27610650; https://doi.org/10.1080/19420862.2016.1208330
   PubMed Web of Science ®Google Scholar
• Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs 2015; 7(4):770-7; PMID:26047159; https://doi.org/10.1080/19420862.2015.1043503
   PubMed Web of Science ®Google Scholar
• Zhou J, Mateos F, Ober RJ, Sally Ward E. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol 2005; 345(5):1071-81; PMID:15644205; https://doi.org/10.1016/j.jmb.2004.11.014
   PubMed Web of Science ®Google Scholar
• Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. Antibody structure, prediction and redesign. Biophys Chem 1997; 68(1-3):9-16; PMID:9468606; https://doi.org/10.1016/S0301-4622(96)02266-1
   PubMed Web of Science ®Google Scholar
• Pedotti M, Simonelli L, Livoti E, Varani L. Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin. Int J Mol Sci 2011; 12(1):226-51; PMID:21339984; https://doi.org/10.3390/ijms12010226
   PubMed Web of Science ®Google Scholar
• Brandt JP, Patapoff TW, Aragon SR. Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody. Biophys J 2010; 99(3):905-13; PMID:20682269; https://doi.org/10.1016/j.bpj.2010.05.003
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A 2015; 112(19):5997-6002; PMID:25918417; https://doi.org/10.1073/pnas.1408766112
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49(2):162-75; PMID:19179295; https://doi.org/10.1177/0091270008329556
   PubMed Web of Science ®Google Scholar
• Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: Blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010; 29(1):48-52; PMID:20430307; https://doi.org/10.1016/j.sder.2010.02.001
   PubMed Web of Science ®Google Scholar
• Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther 2009; 9(8):1107-13; PMID:19569977; https://doi.org/10.1517/14712590903092188
   PubMed Web of Science ®Google Scholar
• Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160(4):810-20; PMID:20590580; https://doi.org/10.1111/j.1476-5381.2010.00702.x
   PubMed Web of Science ®Google Scholar
• Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013; 56(4):660-74; PMID:23917469; https://doi.org/10.1016/j.molimm.2013.05.008
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pl reduces non-specific binding and improves the pharmacokinetics. MAbs 2015; 7(3):483-93; PMID:25695748; https://doi.org/10.1080/19420862.2015.1016696
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40(8):1545-55; PMID:22584253; https://doi.org/10.1124/dmd.112.045864
   PubMed Web of Science ®Google Scholar
• Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68:729-77; PMID:10872465; https://doi.org/10.1146/annurev.biochem.68.1.729
   PubMed Web of Science ®Google Scholar
• Fuster MM, Esko JD. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5(7):526-42; PMID:16069816; https://doi.org/10.1038/nrc1649
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lukacova V, Bartus V, Nie X, Sun G, Manivannan E, Ghorpade SR, Jin X, Manyem S, Sibi MP, et al. Binding of matrix metalloproteinase inhibitors to extracellular matrix: 3D-QSAR analysis. Chem Biol Drug Des 2008; 72(4):237-48; PMID:18844670; https://doi.org/10.1111/j.1747-0285.2008.00710.x
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel 2013; 26(10):663-70; PMID:24046438; https://doi.org/10.1093/protein/gzt047
   PubMed Web of Science ®Google Scholar
• Lueking A, Beator J, Patz E, Müllner S, Mehes G, Amersdorfer P. Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays. Biotechniques 2008; 45(4):1-6; PMID:18855764; https://doi.org/10.2144/000112898
   PubMedGoogle Scholar
• Frese K, Eisenmann M, Ostendorp R, Brocks B, Pabst S. An automated immunoassay for early specificity profiling of antibodies. MAbs 2013; 5(2):279-87; PMID:23412646; https://doi.org/10.4161/mabs.23539
   PubMed Web of Science ®Google Scholar
• Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39(9):1469-77; PMID:21610128; https://doi.org/10.1124/dmd.111.039453
   PubMed Web of Science ®Google Scholar
• Yeung YA, Wu X, Reyes AE, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70(8):3269-77; PMID:20354184; https://doi.org/10.1158/0008-5472.CAN-09-4580
   PubMed Web of Science ®Google Scholar
• Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15(7):637-40; PMID:9219265; https://doi.org/10.1038/nbt0797-637
   PubMed Web of Science ®Google Scholar
• Medesan C, Cianga P, Mummert M, Stanescu D, Ghetie V, Ward ES. Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site. Eur J Immunol 1998; 28(7):2092-100; PMID:9692877; https://doi.org/10.1002/(SICI)1521-4141(199807)28:07%3c2092::AID-IMMU2092%3e3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance: Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282(3):1709-17; PMID:17135257; https://doi.org/10.1074/jbc.M607161200
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33):23514-24; PMID:16793771; https://doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176(1):346-56; PMID:16365427; https://doi.org/10.4049/jimmunol.176.1.346
   PubMed Web of Science ®Google Scholar
• Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279(8):6213-6; PMID:14699147; https://doi.org/10.1074/jbc.C300470200
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182(12):7663-71; PMID:19494290; https://doi.org/10.4049/jimmunol.0804182
   PubMed Web of Science ®Google Scholar
• Souders CA, Nelson SC, Wang Y, Crowleya AR, Klempner MS, Thomas W. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs 2015; 7(5):912-21; PMID:26018774; https://doi.org/10.1080/19420862.2015.1054585
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 2015; 7(2):331-43; PMID:25658443; https://doi.org/10.1080/19420862.2015.1008353
   PubMed Web of Science ®Google Scholar
• Walters BT, Jensen PF, Larraillet V, Lin K, Patapoff T, Schlothauer T, Rand KD, Zhang J. Conformational destabilization of immunoglobulin G increases the low pH binding affinity with the neonatal Fc receptor. J Biol Chem 2016; 291(4):1817-25; PMID:26627822; https://doi.org/10.1074/jbc.M115.691568
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35(1):86-94; PMID:17050651; https://doi.org/10.1124/dmd.106.011734
   PubMed Web of Science ®Google Scholar
• Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C; European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001; 21(1):15-23; PMID:11180276; https://doi.org/10.1002/jat.727
   PubMed Web of Science ®Google Scholar
• Rahavendran SV, Vekich S, Skor H, Batugo M, Nguyen L, Shetty B, Shen Z. Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS. Bioanalysis 2012; 4(9):1077-95; PMID:22612688; https://doi.org/10.4155/bio.12.85
   PubMed Web of Science ®Google Scholar
• Musteata FM. Pharmacokinetic applications of microdevices and microsampling techniques. Bioanalysis 2009; 1(1):171-85; PMID:21083195; https://doi.org/10.4155/bio.09.18
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18(12):1759-69; PMID:17077181; https://doi.org/10.1093/intimm/dxl110
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 2013; 5(3):397-405; PMID:23549129; https://doi.org/10.4161/mabs.23836
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica 2014; 44(12):1127-34; PMID:25030041; https://doi.org/10.3109/00498254.2014.941963
   PubMed Web of Science ®Google Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs 2016; 862(8):1064-78; PMID:27232760;https://doi.org/10.1080/19420862.2016.1193660; https://doi.org/10.1080/19420862.2016.1193660
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010; 602:93-104; PMID:20012394; https://doi.org/10.1007/978-1-60761-058-8_6
   PubMedGoogle Scholar
• Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 2014; 65(1):148-53; PMID:23867339; https://doi.org/10.1016/j.ymeth.2013.07.005
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 2011; 3(1):61-6; PMID:20962582; https://doi.org/10.4161/mabs.3.1.13799
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu C-P, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies. Clin Pharmacokinet 2011; 50(2):131-42; PMID:21241072; https://doi.org/10.2165/11537430-000000000-00000
   PubMed Web of Science ®Google Scholar
• Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31(4):253-63; PMID:20437464; https://doi.org/10.1002/bdd.708
   PubMed Web of Science ®Google Scholar
• Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, Murayama N, Kurihara A, Okudaira N, Izumi T. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011; 26(4):423-30; PMID:21606605; https://doi.org/10.2133/dmpk.DMPK-11-RG-011
   PubMed Web of Science ®Google Scholar
• Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J Clin Pharmacol 2009; 49(12):1382-402; PMID:19837907; https://doi.org/10.1177/0091270009337134
   PubMed Web of Science ®Google Scholar
• Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 2009; 36(5):407-20; PMID:19728050; https://doi.org/10.1007/s10928-009-9129-5
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C. ADME of biologics—what have we learned from small molecules? AAPS J 2012; 14(3):410-9; PMID:22484625; https://doi.org/10.1208/s12248-012-9353-6
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49(10):633-59; PMID:20818831; https://doi.org/10.2165/11535960-000000000-00000
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C. ADME of Biologics—What Have We Learned from Small Molecules? AAPS J. 2012; 14(3):410-9; PMID:22484625
   PubMed Web of Science ®Google Scholar
• Wang J, Iyer S, Fielder PJ, Davis JD, Deng R. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: Comparative evaluation of prediction approaches in early drug development. Vol. 37, Biopharmaceutics and Drug Disposition 2016; 51-65; PMID:25869767
   PubMed Web of Science ®Google Scholar